Novel nanoparticles deliver innovative cancer chemoimmunotherapy
University of Pittsburgh researchers have designed cancer-fighting nanoparticles that co-deliver a chemotherapy drug and a novel immunotherapy
List view / Grid view
University of Pittsburgh researchers have designed cancer-fighting nanoparticles that co-deliver a chemotherapy drug and a novel immunotherapy
A new pre-clinical study has utilised nanoparticles to attach immune-activating molecules to cancer cells.
A study has shown that mRNA delivered via lipid nanoparticles blocks multiple variants of SARS-CoV-2 from entering cells in mice.
12 October 2022 | By Unchained Labs
Watch this on-demand webinar to see first-hand data results demonstrating the power and flexibility of Unagi for nucleic acids, LNPs and AAVs.
Victoria Rees and Ria Kakkad from Drug Target Review bring you the key takeaways from the ELRIG Drug Discovery 2022 event in London.
Researchers have developed a nanobody that can penetrate the tough exterior of brain cells and untangle misshapen proteins that lead to Parkinson’s disease.
A new single-cell nanoparticle targeting-sequencing approach can measure the cellular uptake of lipid nanoparticles carrying mRNA therapies.
Researchers have developed a ground-breaking microscopy technique that allows proteins, DNA, and other tiny biological particles to be studied in their natural state in a completely new way.
Tested using a new brain tissue model, researchers have developed nanoparticles which may be able to deliver chemotherapy drugs for glioblastoma.
The new nanotechnology left six of 10 mice with lymphoma tumour-free and was effective in melanoma when combined with existing drugs.
A new study provides an in-depth review on the designs and applications of morphology-transformable nanoparticles to improve cancer therapies.
The new nanoparticle uses a peptide to target the vascular cell adhesion molecule 1 and reduced the size of vascular lesions in a mouse study.
The new nanoparticle adjuvant improved antibody production following vaccination against HIV, diphtheria and influenza in mouse models.
The new study modelled the process of capsid disassembly of the hepatitis B virus at an atomic level to help develop targeted therapies.
A newly developed blood vessel model can mimic the states of health and disease, paving the way for cardiovascular drug advancements.